Werewolf Therapeutics executives will discuss their cancer therapies at the Jefferies Global Healthcare Conference on June 5, 2025.
Quiver AI Summary
Werewolf Therapeutics, Inc. announced that its President and CEO, Daniel J. Hicklin, Ph.D., along with Chief Medical Officer Randi Isaacs, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 4:20 PM EDT. The event will focus on the company's innovative biopharmaceuticals aimed at activating the immune system to treat cancer, utilizing its proprietary PREDATOR® platform. Werewolf is advancing its clinical candidates, WTX-124 and WTX-330, which are designed to selectively activate in tumor environments, addressing limitations in traditional therapies. A live webcast of the presentation will be available, with an archived replay accessible for 90 days afterward. For more information, visit the company's website.
Potential Positives
- Participation in the Jefferies Global Healthcare Conference highlights Werewolf Therapeutics' commitment to engagement with the investment community and showcases its innovative approach to cancer treatment.
- The company's focus on conditionally activated therapeutics represents a cutting-edge development in immunotherapy, potentially addressing limitations of existing treatment approaches.
- Advancement of clinical stage product candidates WTX-124 and WTX-330 demonstrates ongoing progress in the company’s pipeline, which could lead to new treatment options for patients with solid tumors and Non-Hodgkin Lymphoma.
- The proprietary PREDATOR® platform underpins Werewolf's differentiated strategy in designing therapeutics, reinforcing the potential for significant impact in the biopharmaceutical space.
Potential Negatives
- e
FAQ
What is Werewolf Therapeutics, Inc.?
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics to treat cancer and immune-mediated conditions.
When is Werewolf's fireside chat at the Jefferies Global Healthcare Conference?
The fireside chat is scheduled for 4:20 PM EDT on Thursday, June 5, 2025.
How can I access the live webcast of the presentation?
The live webcast can be accessed via the link at https://investors.werewolftx.com/news-and-events/events.
What are the main therapeutic candidates being developed by Werewolf?
Werewolf is developing WTX-124 and WTX-330, conditionally activated Interleukin-2 and Interleukin-12 molecules for treating solid tumors.
What distinguishes Werewolf's INDUKINE molecules?
INDUKINE molecules are designed to remain inactive in peripheral tissues and selectively activate within the tumor microenvironment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HOWL Insider Trading Activity
$HOWL insiders have traded $HOWL stock on the open market 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $HOWL stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 3 purchases buying 536,426 shares for an estimated $487,187 and 0 sales.
- ANSBERT GADICKE sold 4,386 shares for an estimated $4,605
- LUKE EVNIN sold 2,425 shares for an estimated $2,546
- BIOVENTURES 2014, L.P. MPM sold 1,963 shares for an estimated $2,061
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HOWL Hedge Fund Activity
We have seen 29 institutional investors add shares of $HOWL stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,000,594 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,960,879
- EAGLE HEALTH INVESTMENTS LP removed 700,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,036,000
- PFM HEALTH SCIENCES, LP removed 398,945 shares (-13.7%) from their portfolio in Q1 2025, for an estimated $387,854
- BIT CAPITAL GMBH removed 241,056 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $234,354
- MILLENNIUM MANAGEMENT LLC added 188,328 shares (+31.6%) to their portfolio in Q1 2025, for an estimated $183,092
- DIMENSIONAL FUND ADVISORS LP removed 110,139 shares (-56.6%) from their portfolio in Q1 2025, for an estimated $107,077
- POINT72 ASSET MANAGEMENT, L.P. removed 109,816 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $162,527
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025.
A live webcast link for the presentation will be available at https://investors.werewolftx.com/news-and-events/events . An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF ® , the WEREWOLF logo, PREDATOR ® , INDUKINE ™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
